No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis

Yang An,1,2 Zhaohui Bai,1,2 Xiangbo Xu,1,2 Xiaozhong Guo,1 Fernando Gomes Romeiro,3 Cyriac Abby Philips,4 Yingying Li,5 Yanyan Wu,1,6 and Xingshun Qi1

1Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang 110840, China
2Postgraduate College, Shenyang Pharmaceutical University, Shenyang 110016, China
3Department of Internal Medicine, Botucatu Medical School, UNESP-Univ Estadual Paulista. Av. Prof. Mário Rubens Giimaráes Montenegro, s/n Distrito de Rubião Jr, Botucatu, Brazil
4The Liver Unit and Monarch Liver Lab, Cochin Gastroenterology Group, Ernakulam Medical Center, Kochi, 682028 Kerala, India
5Department of Gastroenterology, The First People’s Hospital of Huainan, Huainan 232007, China
6Postgraduate College, Jinzhou Medical University, Jinzhou 121001, China

Correspondence should be addressed to Xingshun Qi; xingshunqi@126.com

Received 28 February 2020; Revised 25 May 2020; Accepted 1 June 2020; Published 27 June 2020

Background and Aims. Acute upper gastrointestinal bleeding (AUGIB) is one of the most life-threatening emergency conditions. Hemostatic drugs are often prescribed to control AUGIB in clinical practice but have not been recommended by major guidelines and consensus. The aim of this study was to investigate the therapeutic effect of hemostatic drugs on AUGIB in cirrhosis.

Methods. All cirrhotic patients with AUGIB who were admitted to our hospital from January 2010 to June 2014 were retrospectively included. Patients were divided into hemostatic drugs and no hemostatic drug groups. A 1 : 1 propensity score matching (PSM) analysis was performed by adjusting age, gender, etiology of liver disease, Child-Pugh score, MELD score, hematemesis, red blood cell transfusion, vasoactive drugs, antibiotics, proton pump inhibitors, and endoscopic variceal therapy. Primary outcomes included 5-day rebleeding and in-hospital mortality. Results. Overall, 982 cirrhotic patients with AUGIB were included (870 in hemostatic drugs group and 112 in no hemostatic drug group). In overall analyses, hemostatic drugs group had a significantly higher 5-day rebleeding rate (18.10% versus 5.40%, P = 0.001) than no hemostatic drug group; in-hospital mortality was not significantly different between them (7.10% versus 4.50%, P = 0.293). In PSM analyses, 172 patients were included (86 patients in each group). Hemostatic drugs group still had a significantly higher 5-day rebleeding rate (15.10% versus 5.80%, P = 0.046); in-hospital mortality remained not significantly different (7.00% versus 3.50%, P = 0.304) between them. Statistical results remained in PSM analyses according to the type of hemostatic drugs.

Conclusions. The use of hemostatic drugs did not improve the in-hospital outcomes of cirrhotic patients with AUGIB.

1. Introduction

Acute upper gastrointestinal bleeding (AUGIB) is a life-threatening and frequent complication in cirrhosis with its mortality approaching 5-20% [1–4]. About 70% of AUGIB episodes in cirrhosis are due to esophageal variceal rupture secondary to portal hypertension [5]. The primary goals of therapy of AUGIB in liver cirrhosis are initial control of bleeding and prevention of early rebleeding [1, 5, 6]. According to the current guidelines, the mainstay pharmacological management of AUGIB should be the use of vasoactive drugs (terlipressin and somatostatin or its analogues), which can reduce portal blood flow and portal pressure [6–8].
Traditionally, it has been considered that variceal rupture bleeding is potentially more dangerous in cirrhosis due to the underlying coagulation abnormalities [9, 10]. In clinical practice, though not recommended, treating physicians arbitrarily prescribe hemostatic drugs, which act on vasculature or coagulation cascade, as adjuvants for control of bleeding [11]. However, the therapeutic effect of hemostatic drugs on AUGIB remains uncertain. The results of a recent meta-analysis showed that antifibrinolytic agents were deleterious in patients with acute or chronic liver disease and AUGIB [12]. Herein, we conducted a retrospective study to investigate the effect of hemostatic drugs on AUGIB in patients with liver cirrhosis.

2. Methods

The study was approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command with an approval number [number K (2019)32] and was performed according to the Declaration of Helsinki.

2.1. Study Design. In this retrospective study, a total of 1026 cirrhotic patients with AUGIB who were consecutively admitted to the General Hospital of Northern Theater Command from January 2010 to June 2014 were screened. The inclusion criteria were as follows: (1) a diagnosis of liver cirrhosis, and (2) a diagnosis of AUGIB presenting with hematemesis and/or melena at admission. The exclusion criteria were as follows: (1) no episodes of gastrointestinal bleeding within 5 days before admission, and (2) only positive occult blood test. Age, sex, source of gastrointestinal bleeding, cause of liver disease, and malignancy were not limited. Repeated admission was not excluded. Finally, 982 patients were included in our study.

The following data was extracted from our retrospective database: demographic data (i.e., age and gender), etiology of liver disease, presence of hematemesis and/or melena at admission, and laboratory tests (i.e., red blood cell, hemoglobin, white blood cell, platelet count, total bilirubin, direct bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transeptidase, blood urea nitrogen, creatinine, potassium, sodium, prothrombin time, activated partial thromboplastin time, and international normalized ratio [INR]). The Child-Pugh score and model for end-stage liver disease (MELD) score were calculated. The use of red blood cell transfusion and antibiotics as well as the use of vasoactive drugs (i.e., somatostatin and/or octreotide) and proton pump inhibitors (PPIs) were recorded. The grade of esophageal varices was evaluated [13]. The use of endoscopic variceal therapy, Sengstaken-Blakemore tube, and splenectomy with or without devascularization were also recorded.

Hemostatic drugs employed in our study included drugs acting on vascular wall or platelet (i.e., norepinephrine, carbazochrome sodium sulfonate, and Yunnan Baiyao), antifibrinolytic drugs (i.e., ethylenediamine diacetoacidic), thrombin (i.e., lyophilizing thrombin powder), hemocogulase (i.e., snake venom hemocogulase), and procoagulant drugs (i.e., vitamin K). Modes of administration included intravenous, oral, and topical administration. The mechanisms and indications of various hemostatic drugs are shown in Supplementary Table 1.

According to the use of these hemostatic drugs during hospitalization, we divided the patients into hemostatic drugs and no hemostatic drug groups. The major outcomes included a 5-day rebleeding rate and in-hospital mortality. Five-day rebleeding was defined as the recurrence of hematemesis and fresh melena within 5 days after the initial bleeding episode was completely controlled [3].

2.2. Statistical Analyses. Continuous variables were expressed as mean ± standard deviation and median (range). Categorical variables were expressed as frequency (percentage). Nonparametric Mann-Whitney U test was used for continuous variables, and chi-square test was used for categorical variables to compare the differences between hemostatic drugs and no hemostatic drug groups. A 1:1 propensity score matching (PSM) analysis was used. Matching factors included age, gender, etiology of liver diseases, which mainly include hepatitis B, hepatitis C, alcohol abuse, drug abuse, and autoimmunity, Child-Pugh score, MELD score, hematemesis, red blood cell transfusion, vasoactive drugs, antibiotics, PPIs, and endoscopic variceal therapy. After exclusion of patients with malignancy and those who underwent surgery, subgroup analyses were conducted in patients with Child-Pugh class B and C, MELD score > 15 [14], and use of endoscopic variceal therapy and antibiotics. All statistical analyses were performed with IBM SPSS software version 20.0 (IBM Corp, Armonk, NY, USA) and Stata/SE 12.0 (Stata Corp, College Station, TX, USA) software. A histogram demonstrating the frequency of various hemostatic drugs used during the study period was drawn by the Excel version 10.0 (Microsoft Corp, Redmond Washington, USA).

3. Results

3.1. Overall Analyses. A total of 982 patients with cirrhosis and AUGIB were included in our study. Baseline characteristics of patients at admission were shown in Table 1. The median age was 56.01 years (range: 6.28-95.13 years), and most patients were male (n = 688, 70.1%). Hepatitis B virus (n = 399, 40.6%) was the most common etiology of cirrhosis. One hundred and eighty-nine patients (19.2%) had malignancy, including 160 patients with liver cancer and 29 patients with extrahepatic cancer (i.e., lung cancer, breast cancer, gastric cancer, and rectal cancer). Most patients were in Child-Pugh class B (476/982, 52.80%). The median MELD score was 6.60 (range: -7.52-40.95). Endoscopy was performed in 702 patients. Detailed information regarding the grade of esophageal varices on endoscopy was clearly available in 563 patients. Hemostatic drugs group had a higher proportion of hematemesis at admission, lower levels of red blood cell, platelet count, albumin, and alkaline phosphatase, and higher levels of blood urea nitrogen, potassium, prothrombin time, and INR than no hemostatic drug group.

Blood transfusion was given in 640 (65.20%) patients, of whom 611 (62.20%) received red blood cell transfusion with a median of 4 units (range: 1.00-33.00). Somatostatin and/or
| Variables                              | No. Pts | Overall        | No. Pts | Hemostatic drug group | No. Pts | No hemostatic drug group | P value |
|----------------------------------------|---------|----------------|---------|-----------------------|---------|--------------------------|---------|
| Age (years)                            | 982     | 56.01 (6.28-95.13) | 870     | 56.01 (6.28-95.13)     | 112     | 55.45 (24.92-84.77)     | 0.536   |
| Sex (male) (%)                         | 982     | 688 (70.10%)    | 870     | 608 (69.90%)          | 112     | 80 (71.40%)             | 0.737   |
| Cancer (%)                             | 982     | 189 (19.20%)    | 870     | 169 (19.40%)          | 112     | 20 (17.90%)             | 0.692   |
| Liver cancer (%)                       | 982     | 160 (16.30%)    | 870     | 142 (16.30%)          | 112     | 18 (16.10%)             | 0.946   |
| Extrahepatic cancer (%)                | 982     | 29 (3.00%)      | 870     | 27 (3.10%)            | 112     | 2 (1.80%)               | 0.438   |
| Clinical features of AUGIB (%)         |         |                |         |                       |         |                          |         |
| Hematemesis (%)                        | 982     | 587 (59.80%)    | 870     | 541 (62.20%)          | 112     | 46 (41.10%)             | <0.001  |
| Melena (%)                             | 982     | 770 (78.40%)    | 870     | 675 (77.60%)          | 112     | 95 (84.80%)             | 0.080   |
| Hematemesis and melena (%)             | 982     | 375 (38.20%)    | 870     | 346 (39.80%)          | 112     | 29 (25.90%)             | 0.004   |
| Etiology of liver diseases             | 982     |                | 870     |                        | 112     |                          | 0.305   |
| HBV (%)                                | 982     | 399 (40.60%)    | 870     | 359 (41.30%)          | 112     | 40 (35.70%)             | 0.260   |
| HCV (%)                                | 982     | 83 (8.50%)      | 870     | 75 (8.60%)            | 112     | 8 (7.10%)               | 0.597   |
| Alcohol abuse (%)                      | 982     | 354 (36.00%)    | 870     | 315 (36.20%)          | 112     | 39 (34.80%)             | 0.774   |
| HBV+alcohol abuse (%)                  | 982     | 106 (10.80%)    | 870     | 94 (10.80%)           | 112     | 12 (10.70%)             | 0.977   |
| HCV+alcohol abuse (%)                  | 982     | 18 (1.80%)      | 870     | 14 (1.60%)            | 112     | 4 (3.60%)               | 0.145   |
| Other or unknown etiology (%)          | 982     | 186 (18.90%)    | 870     | 159 (18.30%)          | 112     | 27 (24.10%)             | 0.138   |
| Endoscopic evaluation of EV (%)        | 982     | 563 (57.30%)    | 870     | 503 (57.80%)          | 112     | 60 (53.60%)             | 0.393   |
| No EV (%)                              | 982     | 34 (3.50%)      | 870     | 26 (3.00%)            | 112     | 8 (7.10%)               | 0.024   |
| Mild EV (%)                            | 982     | 27 (2.70%)      | 870     | 26 (3.00%)            | 112     | 1 (0.90%)               | 0.202   |
| Moderate EV (%)                        | 982     | 66 (6.70%)      | 870     | 60 (6.90%)            | 112     | 6 (5.40%)               | 0.540   |
| Severe EV (%)                          | 982     | 437 (44.50%)    | 870     | 392 (45.10%)          | 112     | 45 (40.20%)             | 0.328   |
| Laboratory tests                       |         |                |         |                       |         |                          |         |
| Red Blood Cell (10^{12}/L)             | 973     | 2.54 (0.79-5.94)| 864     | 2.52 (0.79-5.49)      | 109     | 2.81 (1.21-5.08)        | 0.002   |
| Hemoglobin (g/L)                       | 974     | 72.00 (19.00-180.00) | 865     | 72.00 (19.00-180.00)   | 109     | 75.00 (31.00-170.00)    | 0.165   |
| White blood cell (10^{9}/L)            | 974     | 4.90 (0.80-46.10)| 865     | 4.90 (0.80-46.10)     | 109     | 4.50 (1.10-30.70)       | 0.658   |
| Platelet (10^{9}/L)                    | 974     | 76.00 (9.00-842.00) | 865     | 76.00 (9.00-775.00)    | 109     | 84.00 (17.00-842.00)    | 0.010   |
| Total bilirubin (μmol/L)               | 964     | 20.70 (3.30-553.60) | 855     | 20.60 (3.30-553.60)    | 109     | 22.60 (5.90-241.40)     | 0.857   |
| Albumin (g/L)                          | 949     | 29.90 (9.60-49.30) | 841     | 29.60 (9.60-49.30)     | 108     | 31.45 (13.60-48.40)     | 0.002   |
| Alanine aminotransferase (U/L)         | 962     | 29.69 ± 6.75  | 853     | 29.43 ± 6.69           | 109     | 31.66 ± 6.94            | 0.764   |
| Variables                              | No. Pts | Overall            | No. Pts | Hemostatic drug group | No. Pts | No hemostatic drug group | P value |
|---------------------------------------|---------|--------------------|---------|-----------------------|---------|--------------------------|---------|
| Aspartate aminotransferase (U/L)      | 903     | 24.00 (5.00-1064.00) | 37.64 ± 61.52 | 24.00 (5.00-1064.00) | 37.66 ± 62.94 | 24.00 (5.00-438.00) | 37.40 ± 49.23 |
|                                       |         |                    | 24.00 (7.00-1487.00) | 58.93 ± 117.01 | 32.00 (7.00-1487.00) | 58.87 ± 117.48 | 31.00 (13.00-994.00) | 59.39 ± 113.76 |
|                                       |         |                    | 74.90 (1.30-889.00) | 99.86 ± 88.33 | 73.00 (1.30-889.00) | 97.68 ± 85.57 | 84.00 (28.00-868.00) | 116.92 ± 106.48 |
|                                       |         |                    | 40.00 (5.00-1168.00) | 87.40 ± 126.42 | 39.00 (5.00-1168.00) | 83.96 ± 119.53 | 48.00 (10.00-994.00) | 114.36 ± 169.35 |
| Blood urea nitrogen (mmol/L)          | 932     | 7.81 (1.54-55.01)  | 9.12 ± 5.99 | 7.94 (1.54-49.19)  | 9.28 ± 5.85 | 6.19 (2.22-55.01)  | <0.001 |
| Serum creatinine (µmol/L)             | 930     | 60.20 (20.00-1189.00) | 72.69 ± 69.59 | 61.00 (20.00-1189.00) | 72.43 ± 66.07 | 57.00 (28.00-919.00) | 74.77 ± 93.11 |
| Potassium (mmol/L)                    | 952     | 4.07 (2.13-7.87)   | 4.11 ± 0.55 | 4.09 (2.13-7.87)   | 4.13 ± 0.57 | 4.00 (2.79-5.80)   | 4.00 ± 0.43 |
| Sodium (mmol/L)                       | 952     | 138.60 (83.00-160.80) | 138.17 ± 5.14 | 138.70 (83.00-160.10) | 138.22 ± 5.14 | 138.00 (118.70-160.80) | 137.84 ± 5.21 |
| Prothrombin time (seconds)            | 922     | 16.20 (10.80-62.80) | 17.29 ± 4.82 | 16.30 (11.00-62.80) | 17.44 ± 4.89 | 14.95 (10.80-40.90) | 16.13 ± 4.17 |
| INR                                   | 920     | 1.31 (0.77-7.96)   | 1.45 ± 0.58 | 1.33 (0.79-7.96)   | 1.46 ± 0.59 | 1.18 (0.77-4.19)   | <0.001 |
| Child-Pugh score                      | 901     | 7.00 (5.00-15.00)  | 7.78 ± 2.00 | 7.00 (5.00-15.00)  | 7.81 ± 1.95 | 7.00 (5.00-14.00)  | 7.51 ± 2.30 |
| Child-Pugh class A/B/C (%)             | 901     | 256 (28.40%)/476 (52.80%)/169 (18.80%) | 215 (26.90%)/433 (54.30%)/150 (18.80%) | 215 (26.90%)/433 (54.30%)/150 (18.80%) | 215 (26.90%)/433 (54.30%)/150 (18.80%) | 41 (39.80%)/43 (41.70%)/19 (18.40%) | 0.187 |
| MELD score                            | 895     | 6.60 (-7.52-40.95) | 7.59 ± 6.71 | 6.74 (-7.44-39.17) | 7.76 ± 6.64 | 5.21 (-7.52-40.95) | 6.24 ± 7.09 |
| Vasoactive drugs (%)                  | 982     | 892 (90.80%)       | 870 | 815 (93.70%) | 112 | 77 (68.80%) | <0.001 |
| Somatostatin (%)                      | 982     | 814 (82.90%)       | 870 | 755 (86.80%) | 112 | 59 (50.40%) | <0.001 |
| Octreotide (%)                        | 982     | 379 (38.60%)       | 870 | 332 (38.20%) | 112 | 47 (42.00%) | 0.436 |
| Proton-pump inhibitors (%)            | 982     | 967 (98.50%)       | 870 | 864 (99.30%) | 112 | 103 (92.00%) | <0.001 |
| Red blood cell transfusion (%)        | 982     | 611 (62.20%)       | 870 | 561 (64.50%) | 112 | 50 (44.60%) | <0.001 |
| Antibiotics (%)                       | 982     | 668 (47.70%)       | 870 | 416 (47.80%) | 112 | 52 (46.40%) | 0.782 |
| 5-day rebleeding (%)                  | 981     | 163 (16.60%)       | 869 | 157 (18.10%) | 112 | 6 (5.40%) | 0.001 |
| In-hospital death (%)                 | 982     | 67 (6.80%)         | 870 | 62 (7.10%) | 112 | 5 (4.50%) | 0.293 |

Abbreviations: Pts: patients; HBV: hepatitis B virus; HCV: hepatitis C virus; AUGIB: acute upper gastrointestinal bleeding; INR: international normalized ratio; APTT: activated partial thromboplastin time; MELD: model for end-stage liver disease; EV: esophageal varices.
octreotide were given in 892 (90.80%) patients. PPIs were given in 967 (98.50%) patients. Antibiotics were given in 468 (47.70%) patients. Endoscopic variceal therapy was performed in 574 (58.50%) patients. Sengstaken-Blakemore tube placement was given in 20 (1.90%) patients. Splenectomy with and without devascularization was performed in 9 (0.9%) patients. Hemostatic drugs group was more likely to receive blood transfusion, red blood cell transfusion, somatostatin and/or octreotide, and PPIs than no hemostatic drug group.

Among the hemostatic drugs, ethylenediamine diacetoacetic, white-browed snake venom hemocoagulase, and lyophilizing thrombin powder were common hemostatic drugs with a high utilization rate of up to 60%-70%. By contrast, carbazochrome sodium sulfonate, vitamin K, and snake venom hemocoagulase were uncommon hemostatic drugs with a relatively low utilization rate of about 10%. There was a trend in a lower utilization rate of norepinephrine, white-browed snake venom hemocoagulase, and lyophilizing thrombin powder over time. By contrast, there was a trend in a higher utilization rate of carbazochrome sodium sulfonate and snake venom hemocoagulase over time (Figure 1).

The 5-day rebleeding rate was 16.6% (n = 163), and in-hospital mortality was 6.8% (n = 67). Hemostatic drugs group had a significantly higher 5-day rebleeding rate than no hemostatic drug group (18.10% versus 5.40%, P = 0.001). In-hospital mortality was not significantly different between the two groups (7.10% versus 4.00%, P = 0.293). The causes of death included uncontrolled bleeding (n = 40), uncontrolled bleeding with hepatic encephalopathy (n = 5), end-stage liver disease (n = 20), and advanced hepatocellular carcinoma (n = 2).

3.2. PSM Analyses

3.2.1. PSM Analyses of Any Hemostatic Drug. A total of 172 patients were included in PSM analyses. In the hemostatic drugs group (n = 86), most patients (n = 74) started using hemostatic drugs from the day at admission until the bleeding stopped or death, and average duration of hemostatic drugs was 6.99 days (range: 1-41 days); rebleeding occurred in 13 patients during hospitalization, all of which developed after the use of hemostatic drugs. Compared with no hemostatic drug group, hemostatic drugs group had a significantly higher incidence of 5-day rebleeding (15.10% versus 5.80%, P = 0.046). In-hospital mortality was statistically similar between the two groups (7.00% versus 3.50%, P = 0.304) (Table 2).

3.2.2. PSM Analyses of Ethylenediamine Diacetoacetic. A total of 160 patients were included in PSM analyses. In the ethylenediamine diacetoacetic group (n = 80), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of ethylenediamine diacetoacetic. There was no significant difference in the incidence of 5-day rebleeding (15.10% versus 5.80%, P = 0.046). In-hospital mortality was statistically similar between the two groups (7.00% versus 3.50%, P = 0.304) (Table 2).

3.2.3. PSM Analyses of Lyophilizing Thrombin Powder. A total of 140 patients were included in PSM analyses. In the
Table 2: PSM analysis of difference between hemostatic drugs and no hemostatic drug groups.

| Variables                          | No. Pts | Hemostatic drugs group               | No. Pts | No hemostatic drug group      | P value |
|------------------------------------|---------|--------------------------------------|---------|-----------------------------|---------|
| Age (years)                        | 86      | 55.60 (30.37-89.23) 57.00 ± 11.39 | 86      | 55.78 (24.92-84.77) 55.65 ± 11.73 | 0.504   |
| Sex (male) (%)                     | 86      | 60 (69.80%)                          | 86      | 62 (72.10%)                  | 0.737   |
| Cancer (%)                         | 86      | 10 (11.60%)                          | 86      | 16 (18.60%)                  | 0.201   |
| Liver cancer (%)                   | 86      | 8 (9.30%)                            | 86      | 15 (17.40%)                  | 0.117   |
| Extrahepatic cancer (%)            | 86      | 2 (2.30%)                            | 86      | 1 (1.20%)                    | 0.560   |
| Clinical features of AUGIB (%)     |         |                                      |         |                             |         |
| Hematemesis (%)                    | 86      | 33 (38.40%)                          | 86      | 36 (41.90%)                  | 0.641   |
| Melena (%)                         | 86      | 72 (83.70%)                          | 86      | 74 (86.00%)                  | 0.670   |
| Both hematemesis and melena (%)    | 86      | 19 (22.10%)                          | 86      | 24 (27.90%)                  | 0.379   |
| Etiology of liver diseases         |         |                                      |         |                             |         |
| HBV (%)                            | 86      | 22 (25.60%)                          | 86      | 32 (37.20%)                  | 0.100   |
| HCV (%)                            | 86      | 5 (5.80%)                            | 86      | 7 (8.10%)                    | 0.549   |
| Alcohol abuse (%)                  | 86      | 33 (38.40%)                          | 86      | 34 (39.50%)                  | 0.876   |
| HBV+alcohol abuse (%)              | 86      | 6 (7.00%)                            | 86      | 11 (12.80%)                  | 0.201   |
| HCV+alcohol abuse (%)              | 86      | 3 (3.50%)                            | 86      | 4 (4.70%)                    | 0.700   |
| Other or unknown etiology (%)      | 86      | 35 (40.70%)                          | 86      | 29 (33.70%)                  | 0.344   |
| Endoscopic evaluation of EV (%)    | 86      | 53 (61.60%)                          | 86      | 49 (57.00%)                  | 0.535   |
| No EV (%)                          | 86      | 5 (5.80%)                            | 86      | 7 (8.10%)                    | 0.549   |
| Mild EV (%)                        | 86      | 3 (3.50%)                            | 86      | 1 (1.20%)                    | 0.312   |
| Moderate EV (%)                    | 86      | 6 (7.00%)                            | 86      | 5 (5.80%)                    | 0.755   |
| Severe EV (%)                      | 86      | 39 (45.30%)                          | 86      | 36 (41.90%)                  | 0.646   |
| Laboratory tests                   |         |                                      |         |                             |         |
| Red Blood Cell (10^{12}/L)         | 86      | 2.58 (0.93-5.07) 2.67 ± 0.73         | 86      | 2.68 (1.21-4.22) 2.71 ± 0.62 | 0.438   |
| Hemoglobin (g/L)                   | 86      | 73.00 (31.00-157.00) 78.64 ± 24.96    | 86      | 73.50 (42.00-122.00) 74.99 ± 19.85 | 0.608   |
| White blood cell (10^{9}/L)        | 86      | 4.05 (1.00-25.20) 5.35 ± 4.29        | 86      | 4.20 (1.10-30.70) 5.70 ± 4.62 | 0.400   |
| Platelet (10^{9}/L)                | 86      | 70.50 (9.00-775.00) 97.90 ± 96.51     | 86      | 82.00 (17.00-842.00) 111.50 ± 105.11 | 0.103   |
| Total bilirubin (µmol/L)           | 86      | 20.10 (4.80-553.60) 35.42 ± 64.87    | 86      | 23.25 (5.90-241.40) 30.03 ± 30.64 | 0.968   |
| Albumin (g/L)                      | 85      | 30.90 (17.20-49.30) 30.60 ± 6.47     | 85      | 31.20 (13.60-48.00) 31.58 ± 7.12 | 0.337   |
| Alanine aminotransferase (U/L)     | 86      | 26.00 (6.00-184.00) 32.23 ± 24.92     | 86      | 23.00 (5.00-438.00) 37.58 ± 53.46 | 0.548   |
| Aspartate aminotransferase (U/L)   | 86      | 35.50 (8.00-228.00) 49.35 ± 42.70     | 86      | 30.50 (13.00-994.00) 60.43 ± 125.71 | 0.218   |
| Alkaline phosphatase (U/L)         | 86      | 76.30 (36.00-707.00) 114.00 ± 102.19  | 86      | 92.50 (28.00-450.00) 104.13 ± 61.66 | 0.381   |
| Gamma-glutamyl transpeptidase (U/L)| 86      | 55.50 (8.00-1168.00) 131.82 ± 209.08  | 86      | 49.50 (10.00-994.00) 103.97 ± 154.16 | 0.454   |
| Blood urea nitrogen (mmol/L)       | 86      | 7.37 (2.07-24.92) 8.54 ± 4.91        | 86      | 6.20 (2.22-55.01) 8.04 ± 7.18    | 0.177   |
| Serum Creatinine (µmol/L)          | 86      | 55.00 (24.00-449.00) 65.36 ± 49.07    | 86      | 57.00 (28.00-919.00) 72.37 ± 97.01 | 0.565   |
| Potassium (mmol/L)                 | 85      | 4.07 (2.13-5.48) 4.08 ± 0.55         | 85      | 4.00 (2.79-5.80) 4.02 ± 0.45    | 0.430   |
lyophilizing thrombin powder group \((n = 70)\), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of lyophilizing thrombin powder. There was no significant difference in the incidence of 5-day rebleeding \((14.30\% \text{ versus } 5.70\%, P = 0.091)\) or in-hospital mortality \((2.90\% \text{ versus } 2.90\%, P = 0.304)\) between the two groups (Supplementary Table 3).

### 3.2.4. PSM Analyses of White-Browed Snake Venom Hemocoagulase
A total of 128 patients were included in PSM analyses. In the white-browed snake venom hemocoagulase group \((n = 64)\), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of white-browed snake venom hemocoagulase. There was no significant difference in the incidence of 5-day rebleeding \((12.50\% \text{ versus } 4.70\%, P = 0.115)\) or in-hospital mortality \((3.10\% \text{ versus } 3.10\%, P = 1.000)\) between the two groups (Supplementary Table 4).

### 3.2.5. PSM Analyses of Snake Venom Hemocoagulase
A total of 62 patients were included in PSM analyses. In the snake venom hemocoagulase group \((n = 31)\), rebleeding occurred in 6 patients during hospitalization, all of which developed after the use of snake venom hemocoagulase. There was no significant difference in the incidence of 5-day rebleeding \((19.40\% \text{ versus } 9.70\%, P = 0.279)\) or in-hospital mortality \((9.70\% \text{ versus } 3.20\%, P = 0.301)\) between the two groups (Supplementary Table 5).

### 3.2.6. PSM Analyses of Yunnan Baiyao
A total of 98 patients were included in PSM analyses. In the Yunnan Baiyao group \((n = 49)\), rebleeding occurred in 13 patients during hospitalization, all of which developed after the use of Yunnan Baiyao. The incidence of 5-day rebleeding was significantly higher in the Yunnan Baiyao group \((26.50\% \text{ versus } 4.10\%, P = 0.002)\). There was no significant difference in the in-hospital mortality \((12.20\% \text{ versus } 4.10\%, P = 0.140)\) between the two groups (Supplementary Table 6).

### 3.2.7. PSM Analyses of Norepinephrine
A total of 96 patients were included in PSM analyses. In the norepinephrine group \((n = 48)\), rebleeding occurred in 10 patients (6 patients were treated with norepinephrine during the endoscopic variceal therapy procedure and 4 patients were treated with norepinephrine orally) during hospitalization, all of which developed after the use of norepinephrine. The incidence of 5-day rebleeding was significantly higher in the norepinephrine group \((20.80\% \text{ versus } 6.20\%, P = 0.037)\). In-hospital mortality was significantly lower in the norepinephrine group \((0.00\% \text{ versus } 8.30\%, P = 0.041)\) (Supplementary Table 7).

### 3.2.8. PSM Analyses of Carbazochrome Sodium Sulfonate
A total of 62 patients were included in PSM analyses. In the carbazochrome sodium sulfonate group \((n = 31)\), rebleeding occurred in 3 patients during hospitalization, all of which developed after the use of carbazochrome sodium sulfonate. There was no significant difference in the incidence of 5-day rebleeding \((9.70\% \text{ versus } 3.20\%, P = 0.301)\) or in-

### Table 2: Continued.

| Variables                          | No. Pts | Hemostatic drugs group | No. Pts | No hemostatic drug group | \(P\) value |
|------------------------------------|---------|------------------------|---------|-------------------------|-------------|
| Sodium (mmol/L)                    | 85      | 139.40 (128.90-147.30) | 85      | 137.60 (122.60-146.50)  | 0.023       |
| Prothrombin time (seconds)         | 86      | 15.60 (12.90-47.00)    | 86      | 15.25 (10.80-40.90)     | 0.280       |
| INR                                | 86      | 1.25 (0.97-5.21)       | 86      | 1.20 (0.77-4.19)        | 0.219       |
| Child-Pugh score                   | 86      | 7.00 (5.00-14.00)      | 86      | 7.00 (5.00-14.00)       | 0.460       |
| Child-Pugh class A/B/C (%)         | 86      | 29 (33.70%)/42 (48.80%)/15 (17.50%) | 86 | 35 (40.70%)/35 (40.70%)/16 (18.60%) | 0.585 |
| MELD score                         | 86      | 5.27 (-6.44-32.06)     | 86      | 5.09 (-7.52-40.95)      | 0.861       |
| Endoscopic variceal treatment (%)  | 86      | 45 (52.30%)            | 86      | 38 (44.20%)             | 0.285       |
| Vasoactive drugs (%)               | 86      | 67 (77.90%)            | 86      | 65 (75.60%)             | 0.718       |
| Somatostatin (%)                   | 86      | 60 (69.80%)            | 86      | 49 (57.70%)             | 0.082       |
| Octreotide (%)                     | 86      | 31 (36.00%)            | 86      | 40 (46.50%)             | 0.163       |
| Proton-pump inhibitors (%)         | 86      | 83 (96.50%)            | 86      | 84 (97.70%)             | 0.650       |
| Antibiotics (%)                    | 86      | 41 (47.70%)            | 86      | 43 (50.00%)             | 0.760       |
| Red blood cell transfusion (%)     | 86      | 47 (54.70%)            | 86      | 44 (51.20%)             | 0.647       |
| 5-day rebleeding (%)               | 86      | 13 (15.10%)            | 86      | 5 (5.80%)               | 0.046       |
| In-hospital death (%)              | 86      | 6 (7.00%)              | 86      | 3 (3.50%)               | 0.304       |

Abbreviations: Pts: patients; HBV: hepatitis B virus; HCV: hepatitis C virus; AUGIB: acute upper gastrointestinal bleeding; INR: international normalized ratio; APTT: activated partial thromboplastin time; MELD: model for end-stage liver disease; EV: esophageal varices.
hospital mortality (6.50% versus 0.00%, \( P = 0.151 \)) between the two groups (Supplementary Table 8).

3.2.9. PSM Analyses of Vitamin K. A total of 64 patients were included in PSM analyses. In the vitamin K group (\( n = 32 \)), rebleeding occurred in 10 patients during hospitalization, all of which developed after the use of vitamin K. The incidence of 5-day rebleeding was significantly higher in the vitamin K group (31.20% versus 6.20%, \( P = 0.010 \)). There was no significant difference in the in-hospital mortality (15.60% versus 3.10%, \( P = 0.086 \)) between the two groups (Supplementary Table 9).

3.3. Subgroup Analyses

3.3.1. Subgroup Analyses of Patients with Child-Pugh Class B and C after Excluding Patients with Malignancy and Those Undergoing Surgery. After excluding patients with malignancy and those undergoing surgery, 523 patients had Child-Pugh class B and C. Hemostatic drugs group had a significantly higher incidence of 5-day rebleeding (15.90% versus 8.30%, \( P = 0.003 \)), but there was no significant difference in the in-hospital mortality (7.40% versus 3.80%, \( P = 0.323 \)) between the two groups.

3.3.2. Subgroup Analyses of Patients with MELD Score > 15 after Excluding Patients with Malignancy and Those Undergoing Surgery. After excluding patients with malignancy and those undergoing surgery, 79 patients had a MELD score > 15. Hemostatic drugs group had a significantly higher incidence of 5-day rebleeding (15.90% versus 4.30%, \( P = 0.003 \)), but there was no significant difference in the in-hospital mortality (6.10% versus 3.30%, \( P = 0.278 \)) between the two groups.

3.3.3. Subgroup Analyses of Patients Having Esophageal Varices on Endoscopy after Excluding Patients with Malignancy and Those Undergoing Surgery. After excluding patients with malignancy and those undergoing surgery, 471 patients had esophageal varices on endoscopy. There was no significant difference in the incidence of 5-day rebleeding (14.90% versus 8.30%, \( P = 0.218 \)) or in-hospital mortality (3.50% versus 2.10%, \( P = 0.596 \)) between the two groups.

3.3.4. Subgroup Analyses of Patients Receiving Endoscopic Variceal Therapy and Antibiotics after Excluding Patients with Malignancy and Those Undergoing Surgery. After excluding patients with malignancy and those undergoing surgery, 243 patients received both endoscopic variceal therapy and antibiotics. There was no significant difference in the incidence of 5-day rebleeding (18.90% versus 9.50%, \( P = 0.285 \)) or in-hospital mortality (4.50% versus 0.00%, \( P = 0.321 \)) between the two groups.

3.3.5. Subgroup Analyses of Patients with Liver Cancer. There were 160 patients with liver cancer. There was no significant difference in the incidence of 5-day rebleeding (26.10% versus 11.10%, \( P = 0.164 \)) or in-hospital mortality (12.00% versus 11.10%, \( P = 0.915 \)) between the two groups.

4. Discussion

Hemostatic drugs have never been recommended by major practice guidelines and consensus for the management of AUGIB in liver cirrhosis [1]. This is primarily because previous studies did not find any benefit of hemostatic drugs for AUGIB [15–20], which is consistent with our findings. Notably, our overall, PSM, and subgroup analyses suggested that neither 5-day rebleeding rate nor in-hospital mortality was improved by the use of hemostatic drugs. This finding can be explained by the fact that AUGIB in cirrhosis is mainly caused by hemodynamic alterations of portal hypertension, but not coagulation disorder [21–23]. A well-known effect of vasoactive drugs is the visceral vasoconstriction, thus decreasing the portal pressure, so these drugs are the first-line choice of therapy for acute variceal bleeding [23]. By comparison, hemostatic drugs cannot act on portal pressure reduction.

Our study specifically analyzed the effect of different hemostatic drugs in patients with cirrhosis and AUGIB. The findings from PSM analyses performed according to the type of hemostatic drugs were similar to those from overall analysis (Figure 2).

Tranexamic acid is one of the most widely employed antifibrinolytic drugs [24]. A meta-analysis showed that the use of tranexamic acid might not reduce the mortality of AUGIB [15]. Tranexamic acid was administered to few patients in our study, but the majority of our patients received ethylenediamine diacetoacetic which has the same mechanism as tranexamic acid. Therefore, the findings of the previous meta-analysis might be comparable to our finding that ethylenediamine diacetoacetic did not improve the in-hospital outcome of cirrhosis with AUGIB.

The \( \epsilon \)-aminocaproic acid is another antifibrinolytic drug. Gunawa and Runyon reported a potential benefit of \( \epsilon \)-aminocaproic acid for hyperfibrinolysis, defined as abnormal euglobulin lysis time < 120 min, in liver cirrhosis [16]. Among the 37 cirrhotic patients with hyperfibrinolysis who developed bleeding episodes and received \( \epsilon \)-aminocaproic acid, the hemostatic successful rate was 92% (34/37). However, a control group without \( \epsilon \)-aminocaproic acid was lacking and the findings might be inconclusive. By comparison, euglobulin lysis time was not regularly measured in our study, and the use of ethylenediamine diacetoacetic in our patients did not depend on the fibrinolysis status. Therefore, our study could not evaluate the benefits of ethylenediamine diacetoacetic in patients with hyperfibrinolysis.

Thrombin can directly affect the conversion from fibrinogen to fibrin clots and acts on the coagulation cascade [25]. A previous study demonstrated that endoscopic injection of human thrombin was effective for gastric variceal bleeding [26]. Additionally, an Indian prospective study including 20 patients with gastric variceal bleeding showed that endoscopic injection of human thrombin was effective and the hemostatic successful rate was 100% [18]. However, in the two studies, endoscopic injection was the only mode of administration, and only gastric and ectopic varices were treated. By comparison, our patients received oral or local spray of lyophilizing
thrombin powder, and a majority of our patients had esophageal varices.

Hemocoagulase, which is extracted from the venom of a snake, such as Brothrops atrox and Agkistrodon blomhoffii assurensis, has a thrombin-like effect [27]. Recently, a randomized controlled trial demonstrated that the topical spray of hemocoagulase might not significantly increase the rate of hemostatic success as compared with traditional 8% norepinephrine (100% versus 94.0%, \( P = 0.060 \)) [17]. By comparison, in our study, no hemostatic drug was employed as the control group, and intravenous infusion of hemocoagulase was the only mode of administration. Notably, compared with local spray, intravenous infusion can cause hypofibrinogenemia, which may aggravate bleeding. Indeed, this phenomenon has been observed in several case reports [28–30].

Recombinant factor VIIa (rFVIIa) is not sufficiently supported by the current evidence for the management of acute variceal bleeding [6]. Two randomized controlled trials assessed the efficacy of rFVIIa for acute variceal bleeding in patients with cirrhosis [19, 31]. The first study assessed 245 cirrhotic patients with AUGIB by assessing a composite endpoint, which consisted of failure to control bleeding within 24 hours, failure to prevent rebleeding between 24 hours and day 5, or death within 5 days. Compared with placebo, rFVIIa significantly improved the composite endpoint (8% versus 23%, \( P = 0.03 \)) in the subgroup analysis of Child-Pugh B class and C patients with variceal bleeding, despite the overall analysis found that the endpoint was not significantly different between rFVIIa and placebo groups (14% versus 16%, \( P = 0.72 \)). Then, the investigators further selected a total of 256 cirrhotic patients with Child-Pugh class B and C and variceal bleeding in a second study to evaluate the same endpoint. Compared with placebo, rFVIIa did not add any significant benefit (23% versus 20%, \( OR = 0.80, P = 0.37 \)) and had a lower rate of the composite endpoint (13%). Our meta-analysis of the two trials suggested that the difference in the endpoint was not significant between placebo and rFVIIa groups. Therefore, the effect of rFVIIa in cirrhotic patients with AUGIB remains controversial [32].

Vitamin K participates into the formation of coagulation factors II, VII, IX, and X in the liver and is usually used as a supplementary intervention [33]. Cirrhosis reduces the ability of synthesizing vitamin K-dependent clotting factors [34]. But intravenous infusion of vitamin K is not recommended to correct the coagulation abnormalities in cirrhosis with bleeding [20]. Indeed, vitamin K failed to achieve a remarkable benefit in the reduction of INR in cirrhosis patients [35]. Similarly, our study also suggested that intravenous infusion of vitamin K brings no benefit for treating gastrointestinal bleeding in patients with cirrhosis.

Due to the retrospective nature of this study, several limitations should be acknowledged. First, not all patients had Child-Pugh and MELD scores due to missing laboratory data. But we conducted the subgroup analyses according to the Child-Pugh class and MELD score. Second, not all patients underwent endoscopy to determine the presence and severity of gastroesophageal varices. But we conducted the subgroup analysis according to the use of endoscopic variceal therapy. Third, different hemostatic drugs during hospitalization were often combined. Fourth, a decision on the use of hemostatic drugs was arbitrarily made by our physicians. But we attempted to conduct the PSM analysis by adjusting 15 confounding factors that are associated with patients’ outcomes. Finally, some hemostatic drugs were domestic, such as ethylenediamine diacetoacetic. Other hemostatic drugs were traditional Chinese medicine, such as Yunnan Baiyao. Both of them were not available in the West. The new topical hemostatic powder represents a

| Hemostatic drugs                                      | 5-day rebleeding | In-hospital mortality |
|-------------------------------------------------------|------------------|-----------------------|
| vs. no hemostatic drug                                |                  |                       |
| Ethylenediamine diacetoacetic vs. no hemostatic drug  |                  |                       |
| Lyophilizing thrombin powder vs. no hemostatic drug   |                  |                       |
| Vitamin K vs. no hemostatic drug                      |                  |                       |
| White-browed snake venom hemocoagulase vs. no hemostatic drug |                  |                       |
| Carbazochrome sodium sulfonate vs. no hemostatic drug |                  |                       |
| Norepinephrine vs. no hemostatic drug                 |                  |                       |
| Snake venom hemocoagulase vs. no hemostatic drug      |                  |                       |
| Yunnan Baiyao vs. no hemostatic drug                  |                  |                       |

Notes:
1. The light red arrow represents a higher incidence but without any significant difference.
2. The dark red arrow represents a significantly higher incidence.
3. The green arrow represents a significantly lower incidence.
4. The black horizontal line represents a similar incidence.

Figure 2: An overview of our findings.
user-friendly and effective tool in the management of upper gastrointestinal bleeding during endoscopic therapy procedures [36]. However, it has not been available at our hospital.

In conclusion, the effect of hemostatic drugs on AUGIB in cirrhotic patients was unsatisfactory, because the use of hemostatic drugs did not decrease the 5-day rebleeding rate or the in-hospital mortality in cirrhotic patients with AUGIB. Notably, most of the rebleeding events occurred after the initial use of hemostatic drugs. Recent advances in the management of AUGIB should be acknowledged. Future studies should employ more recent data to validate our findings. Additionally, considering the limitations of our study, well-designed randomized controlled trials are still needed in future.

**Abbreviations**

AUGIB: Acute upper gastrointestinal bleeding

INR: International normalized ratio

MELD: Model for end-stage liver disease

HCC: Hepatocellular carcinoma

PPIs: Proton pump inhibitors

PSM: Propensity score matching

rFVIIa: Recombinant factor VIIa

OR: Odds ratio

**Data Availability**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Disclosure**

The abstract was published in the Asian-Pacific Association for the Study of Liver (APASL) 2020 Conference as a poster presentation. Please see the following link https://link.springer.com/content/pdf/10.1007/s12072-020-10030-4.pdf.

**Conflicts of Interest**

The authors declare that there is no conflict of interest in this study.

**Authors’ Contributions**

Y.A. wrote the protocol, reviewed, and searched the literature, collected the data, performed the statistical analysis, and drafted the manuscript. Z.B., Y.L., and Y.W. collected and check the data. Z.B., X.X., X.G., F.G.R., and C.A.P. gave critical comments and revised the manuscript. Y.Q. conceived the work, wrote the protocol, reviewed, and searched the literature, performed the statistical analysis, interpreted the data, and revised the manuscript. All authors read and approved the final manuscript. Yang An, Zhaohui Bai, Xiangbo Xu, and Xiaozhong Guo are co-first authors.

**Acknowledgments**

We are indebted to our study team for establishing and updating our retrospective database, including Junna Dai, Cuihong Zhu, Yun Li, Ying Peng, Zheng Ning, Feifei Hou, Jiancheng, Zhao, Han Deng, Ran Wang, Jing Li, Xintong Zhang, Dan Han, Tingxue Song, Zhong Peng, Wenchun Bao, Yingying Li, Zhaohui Bai, Yang An, and Yanyan Wu of whom all had worked for our study group.

**Supplementary Materials**

Supplementary Table 1: Mechanisms and indications of different hemostatic drugs. Supplementary Table 2: PSM analysis of difference between ethylenediamine diacetoacetic acid and no hemostatic drug groups. Supplementary Table 3: PSM analysis of difference between lyophilizing thrombin powder and no hemostatic drug groups. Supplementary Table 4: PSM analysis of difference between white-browed snake venom hemocoagulase and no hemostatic drug groups. Supplementary Table 5: PSM analysis of difference between snake venom hemocoagulase and no hemostatic drug groups. Supplementary Table 6: PSM analysis of difference between Yunnan Baiyao and no hemostatic drug groups. Supplementary Table 7: PSM analysis of difference between norepinephrine and no hemostatic drug groups. Supplementary Table 8: PSM analysis of difference between carbazochrome sodium sulfonate and no hemostatic drug groups. Supplementary Table 9: PSM analysis of difference between vitamin K and no hemostatic drug groups. (Supplementary Materials)

**References**

[1] G. Garcia-Tsao and J. Bosch, "Management of varices and variceal hemorrhage in cirrhosis," *New England Journal of Medicine*, vol. 362, no. 9, pp. 823–832, 2010.

[2] P. Tandon, K. Bishay, S. Fisher et al., “Comparison of clinical outcomes between variceal and non-variceal gastrointestinal bleeding in patients with cirrhosis,” *Journal of Gastroenterology and Hepatology*, vol. 33, no. 10, pp. 1773–1779, 2018.

[3] Y. Li, H. Li, Q. Zhu et al., “Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis,” *European Journal of Gastroenterology & Hepatology*, vol. 31, no. 11, pp. 1334–1341, 2019.

[4] Y. Li, B. Han, H. Li et al., “Effect of admission time on the outcomes of liver cirrhosis with acute upper gastrointestinal bleeding: regular hours versus off-hours admission,” *Canadian Journal of Gastroenterology and Hepatology*, vol. 2018, Article ID 3541365, 14 pages, 2018.

[5] E. Biecker, "Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management," *World Journal of Gastroenterology*, vol. 19, no. 31, pp. 5035–5050, 2013.

[6] D. Tripathi, A. J. Stanley, P. C. Hayes et al., “U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients,” *Gut*, vol. 64, no. 11, pp. 1680–1704, 2015.

[7] X. Zhou, D. Tripathi, T. Song et al., “Terlipressin for the treatment of acute variceal bleeding: a systematic review and meta-analysis of randomized controlled trials,” *Medicine*, vol. 97, no. 48, p. e13437, 2018.
[8] R. de Franchis, “Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices,” *Digestive and Liver Disease*, vol. 36, Supplement 1, pp. S93–100, 2004.

[9] J. Muciño-Bermejo, R. Carrillo-Esper, M. Uribe, and N. Méndez-Sánchez, “Coagulation abnormalities in the cirrhotic patient,” *Annals of Hepatology*, vol. 12, no. 5, pp. 713–724, 2013.

[10] J. Li, X. Qi, H. Deng et al., “Association of conventional haemostasis and coagulation tests with the risk of acute upper gastrointestinal bleeding in liver cirrhosis: a retrospective study,” *Gastroenterology Report*, vol. 4, no. 4, pp. 315–319, 2016.

[11] X. Wang, Y. Liu, J. Zhao, and J. Zhang, “Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage,” *Experimental and Therapeutic Medicine*, vol. 17, pp. 3417–3422, 2019.

[12] A. J. Martí-Carvajal and I. Sola, “Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease,” *Cochrane Database of Systematic Reviews*, no. 6, 2015.

[13] Chinese Society of Gastroenterology CSoH CSoE and Associa-
tion CM, “Consensus on prevention and treatment for gastro-esophageal varices and variceal hemorrhage in liver cirrhosis,” *Zhong hua gan zang bing za zhi*, vol. 16, no. 5, pp. 64–70, 2008.

[14] Y. Peng, X. Qi, and X. Guo, “Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies,” *Medicine*, vol. 95, 2016.

[15] C. Bennett, S. L. Klingenberg, E. Langholz, L. L. Gluud, and Cochrane Upper GI and Pancreatic Diseases Group, “Tranexamic acid for upper gastrointestinal bleeding,” *Cochrane Database of Systematic Reviews*, no. 11, 2014.

[16] B. Gunawan and B. Runyon, “The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis,” *Alimentary Pharmacology and Thera-
pedics*, vol. 23, no. 1, pp. 115–120, 2006.

[17] T. Wang, D. N. Wang, W. T. Liu et al., “Hemostatic effect of topical hemocoagulase spray in digestive endoscopy,” *World Journal of Gastroenterology*, vol. 22, no. 5, pp. 5831–5836, 2016.

[18] A. Jhajharia, S. J. Wanjari, P. Ashdhir, R. Pokharna, and S. Nijhawan, “Role and safety of human thrombin injection for the treatment of bleeding gastric varices,” *Indian Journal of Gastroenterology*, vol. 37, no. 4, pp. 321–325, 2018.

[19] J. Bosch, D. Thabut, A. Albillos et al., “Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial,” *Hepatology*, vol. 47, no. 5, pp. 1604–1614, 2008.

[20] A. J. Martí-Carvajal and I. Sola, “Vitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseases,” *Cochrane Database of Systematic Reviews*, no. 6, 2015.

[21] A. Berzigotti, “Advances and challenges in cirrhosis and portal hypertension,” *BMC Medicine*, vol. 15, no. 1, p. 200, 2017.

[22] P. M. Mannucci and A. Tripodi, “Hemostatic defects in liver and renal dysfunction,” *Hematology*, vol. 2012, no. 1, pp. 168–173, 2012.

[23] G. Garcia-Tsao, J. G. Abraldes, A. Berzigotti, and J. Bosch, “Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases,” *Hepatology*, vol. 65, pp. 310–335, 2016.

[24] I. Q. Molenar, N. Warmaar, H. Groen, E. M. TenVergert, M. J. H. Slooff, and R. J. Porte, “Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis,” *American Journal of Transplantation*, vol. 7, no. 1, pp. 185–194, 2007.

[25] S. G. Williams, R. A. Peters, and D. Westaby, “Thrombin—an effective treatment for gastric variceal haemorrhage,” *Gut*, vol. 35, no. 9, pp. 1287–1289, 1994.

[26] N. C. McAvoy, J. N. Plevris, and P. C. Hayes, “Human thrombin for the treatment of gastric and ectopic varices,” *World Journal of Gastroenterology*, vol. 18, no. 41, pp. 5912–5917, 2012.

[27] N. Marsh and V. Williams, “Practical applications of snake venom toxins in haemostasis,” *Toxicon*, vol. 45, no. 8, pp. 1171–1181, 2005.

[28] X. Qi, J. Wang, X. Yu et al., “Hemocoagulase might not control but worsen gastrointestinal bleeding in an elderly patient with type II respiratory failure,” *Translational Gastroenterology and Hepatology*, vol. 2, no. 9, pp. 71–71, 2017.

[29] H. B. Zhou, “Hypofibrinogenemia Caused by Hemocoagulase After Colon Polyps Excision,” *American Journal of Case Reports*, vol. 18, pp. 291–293, 2017.

[30] X. Linglong and W. Dijiong, “Prolonged hemocoagulase Agkistrodon halys pallas administration induces hypofibrinoge-
genemia in patients with hematological disorders: a clinical analysis of 11 patients,” *Indian Journal of Hematology and Blood Transfusion*, vol. 34, no. 2, pp. 322–327, 2018.

[31] J. Bosch, D. Thabut, F. Bendtsen et al., “Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial,” *Gastroenterology*, vol. 127, no. 4, pp. 1123–1130, 2004.

[32] X. Qi, C. Ye, and X. Guo, “Recombinant factor VIIa for vari-
ceal bleeding in liver cirrhosis: still only a hope,” *Archives of Medical Science*, vol. 13, no. 2, pp. 496–499, 2017.

[33] C. C. Prelupean, C. Fierbinteanu-Bratievici, V. L. Drug, C. Lăcătușu, B. Mihai, and C. Mihai, “Liver cirrhosis–procoagulant stasis,” *Revista medical–chirurgical a Societății de Medic și Naturalisti din Iași*, vol. 115, no. 3, pp. 678–685, 2011.

[34] L. Anitran, M. A. Guardascione, V. Brancaccio, and A. Balzano, “Coagulation disorders in liver disease,” *Seminars in Liver Disease*, vol. 22, no. 1, pp. 083–096, 2002.

[35] R. M. Rivosecchi, S. L. Kane-Gill, J. Garavaglia, A. MacLasco, and H. Johnson, “The effectiveness of intravenous vitamin K in correcting cirrhosis-associated coagulopathy,” *International Journal of Pharmacy Practice*, vol. 25, no. 6, pp. 463–465, 2017.

[36] A. Facciorusso, M. Straus Takahashi, C. Eyileten Postula, V. R. Buccino, and N. Muscatelli, “Efficacy of hemostatic powders in upper gastrointestinal bleeding: a systematic review and meta-analysis,” *Digestive and Liver Disease*, vol. 51, no. 12, pp. 1633–1640, 2019.